The FDA's GRAS status allows supplements to bypass full review, a point targeted by Kennedy and analyzed by experts like Professor Cohen, involving Calley Means and Harvard Medical School.
2 reports, 2 independent
Updated Jul 30
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA's GRAS status allows supplements to bypass full review, a point targeted by Kennedy and analyzed by experts like Professor Cohen, involving Calley Means and Harvard Medical School.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cohen critiques FDA testing standards regarding product review.1 source
- APA research informs expert critique of the institutional review process regarding GRS's status.Sub-event
Kennedy targets the FDA's GRAS loophole allowing supplements to bypass full review, with expert analysis from Harvard Medical School.1 source
Keep exploring
The entities involved
- FDA
-
Consumer Healthcare Products Association
organization
Nothing else this week.
-
Calley Means
American entrepreneur (born 1985)
Nothing else this week.
-
Harvard Medical School
medical school in Boston, Massachusetts
Related events
- Unregulated products are bypassing official government approval processes.
- A facility located in St. George is operating under the standards set by the U.S. Food and Drug Administration (FDA) for supplement manufacturing.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.